Each month, we'll highlight a few of the many trials enrolling volunteers. To view more available trials for various forms of interstitial lung disease (ILD), please visit the 🔍 PFF Clinical Trial Finder.

Phase 2 IPF Study’s Updated Analysis 

In January 2026, Tvardi Therapeutics released results from an additional analysis of its phase 2 REVERT IPF study. This update followed the company’s October 2025 announcement that REVERT IPF did not meet its primary objective based on early safety and effectiveness results.

REVERT IPF studied TTI-101 as a treatment for idiopathic pulmonary fibrosis (IPF), and the secondary analysis reviewed data from 40 participants who received at least 12 weeks of the study drug or placebo. Key findings from this analysis include:

• Patients treated with TTI-101 showed a larger drop in lung fibrosis compared to those on placebo.
• Levels of IL-6, a marker of inflammation, fell more in patients taking TTI-101.
• A higher percentage of patients taking TTI-101 experienced improved lung function after 12 weeks, and overall lung function declined less than in the placebo group.

These findings did not change the original outcome of the trial. However, the additional data may help guide future clinical trials and research. The results highlight the role of clinical studies in generating information that can inform ongoing research, even when a trial does not meet its primary endpoint.

These results highlight the need for ongoing efforts to enhance trial representativeness and ensure findings are successfully adopted into clinical care worldwide.

Geographical Distribution of Phase II/III Pharmaceutical Randomized Controlled Trials in Adults With ILD

The January 2026 issue of CHEST Journal featured an article detailing the findings of a study on the worldwide distribution of pharmaceutical randomized controlled trials (RCTs) for ILD. A RCT is a study in which participants are randomly assigned to the experimental treatment group or the placebo group.

By analyzing phase 2 and 3 trials from ClinicalTrials.gov through February 2024, researchers found that trial activities remain concentrated in North America (70%) and Europe (52%), despite expanding global involvement. While participation has increased in Asia, South America, and Australia over the last two decades, significant geographical disparities persist. The findings indicate that phase 2 and 3 RCT activity correlates positively with a country's Healthcare Access and Quality Index (a scoring system that compares the availability and effectiveness of care in a given location to another location by examining health outcomes), while phase 3 activity and recruiting sites are associated with higher urban population percentages.

PFF CTI Webinar Series February and June 2026

Please join the PFF and industry representatives for the PFF Clinical Trial Innovation (CTI) Webinar Series. You will learn about the development of innovative therapies and advancements in PF and ILD research. The first webinar in this series is on Wednesday, February 11, 2026, and will feature the following clinical trials:

• FOCUSIPF: A Phase 2a Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis
• Trial Sponsor: AbbVie
• A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis (AURORA)
• Trial Sponsor: Calluna Pharma
• ASPIRE-IPF
• Trial Sponsor: Vicore Pharma

Register for the February webinar

The second webinar is on Tuesday, June 23, 2026, and will feature three different studies so make sure you attend both.

Register for the June webinar

If you have any questions or comments about this newsletter, please email partnerships@pulmonaryfibrosis.org.